Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Diabetes/Metabolism Research Reviews

• Publication date

  2006-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/dmrr.646PMID 16634116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

  2006cited by this paper
• Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004influential reference
• Impaired effect of sulfonylurea following increased dosage

  2004cited by this paper
• Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.

  2004cited by this paper
• Weight Effect of Current and Experimental Drugs for Diabetes Mellitus

  2003cited by this paper
• Combination therapies with insulin in type 2 diabetes.

  2001cited by this paper
• Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

  2001cited by this paper
• Long-Term Prevention of Bone Loss

  2000cited by this paper
• Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats.

  2000cited by this paper
• Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

  2000cited by this paper
• Pharmacologic Therapy for Type 2 Diabetes Mellitus

  1999cited by this paper
• Repaglinide versus glyburide: a one-year comparison trial.

  1999cited by this paper
• Mikhail Bulgakov's myth about medicine, literature, and fiction.

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Trends in prescribing calcium-channel blockers

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

  1995cited by this paper
• One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.

  1994cited by this paper
• Sulfonylureas in NIDDM

  1992cited by this paper
• Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurements.

  1988cited by this paper

• A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals

  2025cites this paper
• GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

  2025cites this paper
• Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies

  2024cites this paper
• GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis

  2023cites this paper
• Effect of branched-chain amino acids on food intake and indicators of hunger and satiety- a narrative summary

  2022cites this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

  2022cites this paper
• Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics

  2021influential citation
• Diabetic Pharmacotherapies in Kidney Disease

  2019cites this paper
• GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

  2018cites this paper
• Exenatide prevents diabetic nephropathy in a rat model of type 2 diabetes mellitus (fat-fed and streptozotocin-treated rats)

  2017cites this paper
• New Targets for Drug Treatment of Obesity.

  2017cites this paper
• The role of intestinal hydrogen sulfide on GLP-1 secretion and downstream metabolism

  2017influential citation
• Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists

  2017cites this paper
• A CTUALIZACIÓN E N D IABETES Y E NFERMEDAD C ARDIOVASCULAR

  2016cites this paper
• A systematic review of the safety of incretin-based therapies in type 2 diabetes

  2016cites this paper
• The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide

  2016cites this paper
• Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease

  2015cites this paper
• The role of GLP‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

  2015cites this paper
• Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

  2015cites this paper
• The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

  2015cites this paper
• Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes

  2015cites this paper
• Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease

  2015cites this paper
• Starting Insulin Treatment in Type 2 Diabetes

  2015cites this paper
• American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.

  2015cites this paper
• Therapeutic Class Overview Attention Deficit/Hyperactivity Disorder (ADHD) Agents and Stimulants

  2014cites this paper
• Morbid Obesity in Diabetes Mellitus Type 2 and Exenatide

  2014cites this paper
• Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption

  2014cites this paper
• Glucagon-like peptide-1 in nonalcoholic steatohepatitis

  2014cites this paper
• [Cardioprotective effects of glucagon-like peptide 1 receptor agonists].

  2014cites this paper
• Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

  2013cites this paper
• Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies

  2013cites this paper
• Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

  2013cites this paper
• Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.

  2013cites this paper
• PREDICTIVE FACTORS ASSOCIATED WITH PRIMARY FAILURE TO EXENATIDE AND NON GOAL ATTAINMENT IN PATIENTS WITH TYPE 2 DIABETES

  2012cites this paper
• Animal models to explore the effects of CNS drugs on food intake and energy expenditure.

  2012cites this paper
• Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity

  2012cites this paper
• Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

  2012cites this paper
• Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity

  2012cites this paper
• Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease

  2012cites this paper
• Gastric stimulation for weight loss.

  2012cites this paper
• Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

  2012cites this paper
• GLYCEMIC CONTROL AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES INTENSIFIED TO THREE INSULIN REGIMENS AFTER THERAPEUTIC FAILURE TO EXENATIDE

  2012cites this paper
• Targeting the glucagon receptor family for diabetes and obesity therapy.

  2012cites this paper
• An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists

  2012cites this paper
• Manejo terapéutico de la hiperglucemia en la diabetes tipo 2. Antidiabéticos orales

  2012cites this paper
• Tip 2 diabetes mellitus tedavisinde inkretinler

  2012cites this paper
• Original article Long-term cost-utility analysis ofexenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

  2012cites this paper
• Therapeutic Class Overview Incretin Mimetics &

  2012influential citation
• Alterations in energy balance following exenatide administration.

  2012cites this paper
• Obesity – an indication for GLP‐1 treatment? Obesity pathophysiology and GLP‐1 treatment potential

  2011cites this paper
• Expression And Functional Evaluation Of Exendin 4 Fused To Cholera Toxin B Subunit In Tobacco Chloroplast To Treat Type 2 Diabetes

  2011cites this paper
• The Pharmacological Treatment and Management of Obesity

  2011cites this paper
• Type 2 Diabetes in Adults

  2011cites this paper
• Pharmacological management of type 2 diabetes mellitus: an update.

  2011cites this paper
• Pharmacotherapy for obesity: a field in crisis?

  2011cites this paper
• A review of diabetes treatment adherence and the association with clinical and economic outcomes.

  2011cites this paper
• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan.

  2011cites this paper
• Weight gain associated with antidiabetic medications

  2011cites this paper
• Is the GLP-1 system a viable therapeutic target for weight reduction?

  2011cites this paper
• Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes

  2011cites this paper
• Glucagon-like peptide-1 analogues for type 2 diabetes

  2011cites this paper
• Glucagon-like peptide analogues for type 2 diabetes mellitus.

  2011cites this paper
• Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents

  2011cites this paper
• [Incretin-based therapy for treating patients with type 2 diabetes].

  2011cites this paper
• Physiological aspects of weight loss in obesity

  2011cites this paper
• Pharmacotherapy for obese adolescents.

  2011cites this paper
• Фармакологические эффекты и результаты клинических исследований первого представителя класса инкретиномиметиков

  2011cites this paper
• Marine invertebrate and bacterial extract library screens for novel modulators of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors

  2011cites this paper
• Overweight, Obesity, and Cardiovascular Risk

  2011cites this paper
• A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus

  2010cites this paper
• Exenatide and weight loss.

  2010cites this paper
• Novel, non-peptidic somatostatin receptor subtype 5 antagonists improve glucose tolerance in rodents.

  2010cites this paper
• exenatide once weekly: clinical outcomes and patient satisfaction

  2010cites this paper
• Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite

  2010cites this paper
• Glycaemic control in type 2 diabetes: targets and new therapies.

  2010cites this paper
• The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review

  2010cites this paper
• Exenatide once weekly: clinical outcomes and patient satisfaction

  2010cites this paper
• Review article Exenatide and weight loss

  2010cites this paper
• One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.

  2010cites this paper
• Treating Type 2 Diabetes Mellitus

  2010cites this paper
• The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults.

  2010cites this paper
• Exenatide

  2009cites this paper
• Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes

  2009cites this paper
• When prevention fails: obesity treatment strategies.

  2009cites this paper
• Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

  2009cites this paper
• Antidiabetic medications and weight gain: Implications for the practicing physician

  2009cites this paper
• Hipoglicemia e tratamento da diabetes mellitus

  2009cites this paper
• Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes:

  2009cites this paper
• Miméticos do “glucagon-like peptide-1” (GLP-1) e o seu potencial farmacêutico no controlo da diabetes tipo 2 e da obesidade

  2009cites this paper
• The usefulness of a Mediterranean-based diet in individuals with type 2 diabetes

  2009cites this paper
• Exenatide efficacy and safety: a systematic review

  2009cites this paper
• The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake

  2009cites this paper
• Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

  2009cites this paper
• Obesity treatment: novel peripheral targets.

  2009cites this paper
• Incretins: the novel therapy of type 2 diabetes.

  2008cites this paper
• CLINICAL ASPECTS OF OBESITY AND CARDIOMETABOLIC DISEASE Background – Do We Need Drugs for Obesity ?

  2008cites this paper
• Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular

  2008cites this paper
• Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis

  2008cites this paper
• GLP‐1: physiological effects and potential therapeutic applications

  2008cites this paper
• Beyond Glycemic Control

  2008cites this paper